https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
7-6.8months. Compared with DPP-4 inhibitors, the risk of HHF was reduced by 18% and all-cause mortality was reduced by 36% with empagliflozin (HR 0.82; 95% CI 0.71-0.94, and HR 0.64; 95% CI 0.50-0.81, respectively). Reductions were consistent across countries, and in patients with and without baseline cardiovascular disease. ESRD was also significantly reduced with empagliflozin versus DPP-4 inhibitors (HR 0.37; 95% CI 0.24-0.58). Empagliflozin treatment was associated with reduced risk for HHF, all-cause mortality and
Beğen
Yorum Yap
Paylaş
